Tag:

Novartis

Latest Headlines

Latest Headlines

Novartis' Bexsero picks up FDA nod--but with competition looming, approval isn't everything

After years of pinning its vaccine ambitions on meningitis B shot Bexsero, Novartis' FDA approval is here. But as it prepares to fork over the jab--along with the bulk of its vaccines business--to deal partner GlaxoSmithKline, there are other hurdles in the way of its success--including some new competition from Pfizer.

GSK to divest meningitis shots in exchange for EU clearance of Novartis deal

The European Commission has cleared GlaxoSmithKline's deal for most of Novartis' vaccines unit--on a couple of conditions.

Novartis braces for psoriasis pricing war as it preps for Cosentyx launch

Novartis' Cosentyx may be the first next-gen psoriasis treatment to hit the U.S. market, but it certainly won't be the last--and the Swiss drugmaker knows it. So while competitors usher their own prospects down the regulatory pathway, the company is girding for the price war it envisions in its future.

Novartis points to PhIII data to explain weak Jetrea sales

Novartis has admitted that sales of the vitreomacular adhesion drug it licensed from ThromboGenics have failed to live up to expectations. And while various theories have been put forward to explain the drug's relative lack of commercial success, Novartis thinks part of the issue dates back to clinical trials.

Novartis revs up Cosentyx launch as it braces for a psoriasis pricing war

Novartis' Cosentyx may be the first next-gen psoriasis treatment to hit the U.S. market, but it certainly won't be the last--and the Swiss drugmaker knows it. So while competitors usher their own prospects down the regulatory pathway, the company is girding for the price war it envisions in its future.

Novartis eyes more cost-cutting moves to deliver faster-growing profits

Novartis is looking for big things as it doubles down in oncology, hives off vaccines, and teams up with GlaxoSmithKline on consumer health. It's looking for impressive results from its new meds, especially its forthcoming heart failure drug LCZ696 and brand-new psoriasis med Cosentyx. And it's thinking that these changes will help it bear the battering from generic competition.

Novartis, Pfizer and Bristol-Myers hit the gas on R&D last year

Three of the world's largest drugmakers dialed up their R&D budgets in 2014, as Novartis, Pfizer and Bristol-Myers Squibb spent big on costly late-stage programs with hopes of delivering blockbuster new treatments in the coming year.

Psoriasis researchers identify a lineup of suspect proteins behind disease progression

The recent approval of Novartis' Cosentyx marks the first in a whole new lineup of psoriasis drugs coming into the market. But there's still no cure and only a hazy understanding of the root causes of psoriasis. But scientists at Case Western Reserve say they've identified four proteins that they believe may contribute to the disease.

Novartis Q4 profit slumps nearly 27% as sales take a hit

Swiss-based Novartis reported a nearly 27% drop in fourth-quarter profit on Tuesday as lower-than-expected sales hit the bottom line.

Novartis hands off another PhIII drug to Array

That big drug swap between Novartis and GlaxoSmithKline is once again proving to be a boon to Array BioPharma. Array saw its shares spike more than 40% on Friday after the company said that Novartis is handing back rights to the Phase III BRAF inhibitor encorafenib, not long after it also scooped up the rights to binimetinib.